Latterell Venture Partners
Latterell Venture Partners is a venture capital firm specializing in startups and early stage healthcare companies.
Business Model:
Revenue: $7.4M
Employees: 2-10
Rankings
Industries / Tags:
Detailed Latterell Venture Partners Information
Geographic Data
Address: 1 Embarcadero Ctr
City: San Francisco
State: CA
Zip: 94111
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Latterell Venture Partners is a venture capital firm specialized in startups and early stage healthcare companies, including biotechnology, pharmaceutical, research instrument, biomaterial, medical device, healthcare IT, and diagnostic ventures. The firm invests in early stage healthcare companies with innovative technologies, large market opportunities, and passionate entrepreneurs. It offers a collection of venture capital, entrepreneurial, technical, clinical, and collaborative skills enabling entrepreneurs to create successful startups. Founded in 2001, Latterell Venture Partners is based in San Francisco, California.
Contact Phone:
+14153999880
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 4/2017 | Viracta Therapeutics | Series B | 0 |
| 11/2011 | Inova Labs | Series B | 0 |
| 8/2007 | Leptos Biomedical | Series C | 20M |
| 12/2004 | CardioMind | Series B | 15.1M |
| 1/2012 | Transcend Medical | Series B | 16M |
| 2/2008 | Pathway Medical Technologies | Series C | 7.5M |
| 5/2016 | Neuraltus Pharmaceuticals | Venture Round | 0 |
| 1/2012 | Neuraltus Pharmaceuticals | Series B | 9.6M |
| 3/2005 | XTENT | Series C | 25M |
| 11/2005 | Ovalis | Series A | 0 |
| 3/2012 | Viracta Therapeutics | Series B | 0 |
| 5/2007 | Pulmonx | Series B | 20M |
| 1/2011 | TetraLogic Pharmaceuticals | Series C | 0 |
| 12/2012 | Naurex | Series B | 0 |
| 6/2011 | Transcend Medical | Series B | 51M |
| 11/2006 | Pathway Medical Technologies | Series B | 25M |
| 6/2008 | Meritage Pharma | Series A | 22.5M |
| 1/2006 | ProteinSimple | Series B | 0 |
| 5/2007 | Talima Therapeutics | Series B | 19M |
| 9/2008 | Proteolix | Series C | 79M |
| 11/2008 | OncoMed Pharmaceuticals | Series B | 154M |
| 12/2014 | Naurex | Series C | 0 |
| 6/2006 | TetraLogic Pharmaceuticals | Series B | 36M |
| 5/2005 | Bayhill Therapeutics | Series B | 35.4M |
| 1/2004 | Bayhill Therapeutics | Series A | - |
| 4/2014 | Transcend Medical | Series C | 0 |
| 4/2009 | ProteinSimple | Series C | 10M |
| 8/2010 | TetraLogic Pharmaceuticals | Series C | 0 |
| 5/2011 | Naurex | Series A | 18M |
| 9/2008 | ForteBio | Series C | 25M |
| 10/2005 | ForteBio | Series B | 17.3M |
| 4/2006 | Bayhill Therapeutics | Venture Round | 15.8M |
| 9/2005 | OncoMed Pharmaceuticals | Series A | 13.9M |
| 3/2010 | Pulmonx | Series C | 0 |
| 1/2012 | Pulmonx | Private Equity Round | 0 |
| 1/2007 | Ovalis | Series B | 0 |
| 9/2004 | Cellective Therapeutics | Series A | 27.5M |
| 3/2009 | Neuraltus Pharmaceuticals | Series A | 17M |
| 5/2019 | Pulmonx | Series G | 0 |
| 6/2004 | Aria Biosystems | Series A | 5.5M |
| 4/2012 | Neuraltus Pharmaceuticals | Venture Round | 0 |
| 10/2010 | Femta Pharmaceuticals | Series A | 22M |
| 7/2009 | Femta Pharmaceuticals | Venture Round | 1M |
| 5/2009 | Revascular Therapeutics | Series B | 3M |
| 6/2007 | Evoke Pharma | Series A | 3.3M |
| 11/2020 | Viracta Therapeutics | Series E | 0 |
| 7/2007 | CardioMind | Series C | 11M |
| 3/2008 | CardioMind | Venture Round | 22M |
| 10/2010 | ProteinSimple | Series F | 20M |
| 6/2009 | Transcend Medical | Series B | 35M |
| 7/2003 | CardioMind | Series A | 4.5M |
| 6/2010 | Calistoga Pharmaceuticals | Series C | 40M |
| 5/2016 | Aptinyx | Series A | 0 |
| 3/2009 | Pathway Medical Technologies | Series D | 42.5M |
| 11/2020 | Viracta Therapeutics | Series E | 0 |
| 5/2019 | Pulmonx | Series G | 0 |
| 4/2017 | Viracta Therapeutics | Series B | 0 |
| 5/2016 | Neuraltus Pharmaceuticals | Venture Round | 0 |
| 5/2016 | Aptinyx | Series A | 0 |
| 12/2014 | Naurex | Series C | 0 |
| 4/2014 | Transcend Medical | Series C | 0 |
| 12/2012 | Naurex | Series B | 0 |
| 4/2012 | Neuraltus Pharmaceuticals | Venture Round | 0 |
| 3/2012 | Viracta Therapeutics | Series B | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
